This plasticity, referred to as NET, has been identified in more than 14% of patients with EGFR (Epidermal Growth Factor Receptor)-mutated NSCLC in response to resistance to EGFR inhibitor therapy [23,24]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.